Weyerer, V.
29  Ergebnisse:
Personensuche X
?
3

Heterogeneity-analysis of molecular subtypes of muscle-inva..:

Weyerer, V ; Lange, F ; Wullweber, A...
Urologic Oncology: Seminars and Original Investigations.  38 (2020)  12 - p. 907 , 2020
 
?
4

Divergent immunobiological correlates of FDA-/EMA-approved ..:

Weyerer, V ; Geppert, CI ; Bertz, S...
Urologic Oncology: Seminars and Original Investigations.  38 (2020)  12 - p. 908 , 2020
 
?
 
?
6

Cytotoxic T cell related gene expression signature predicts..:

Eckstein, M. ; Wirtz, R. ; Strissel, P....
European Urology Supplements.  18 (2019)  1 - p. e587-e588 , 2019
 
?
7

Performance of FDA/EMA approved PD-L1 assays in urothelial ..:

Eckstein, M. ; Erben, P. ; Kriegmair, M....
European Urology Supplements.  18 (2019)  1 - p. e308-e309 , 2019
 
?
8

Immunological microenvironment of FGFR3 altered muscle-inva..:

Weyerer, V. ; Stoehr, R. ; Bolenz, C....
European Urology Supplements.  18 (2019)  1 - p. e1628 , 2019
 
?
9

The Prognostic Value of FGFR3 Expression in Patients with T..:

Sikic D ; Taubert H ; Breyer J...
https://www.dovepress.com/the-prognostic-value-of-fgfr3-expression-in-patients-with-t1-non-muscl-peer-reviewed-fulltext-article-CMAR.  , 2021
 
?
10

An integrated multi-omics analysis identifies prognostic mo..:

Lindskrog, SV ; Prip, F ; Lamy, P...
https://eprints.whiterose.ac.uk/175946/1/An%20integrated%20multi-omics%20analysis%20identifies%20prognostic%20molecular%20subtypes%20of%20non-muscle-invasive%20bladder%20cancer.pdf.  , 2021
 
?
 
1-15